Efficacy of imeglimin in stepping down from multiple daily insulin injection with DPP-4 inhibitor

Efficacy of imeglimin in stepping down from multiple daily insulin injection with DPP-4 inhibitor - Efficacy of imeglimin in stepping down from multiple daily insulin injection with DPP-4 inhibitor

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058691

Enrollment

Registered

2025-08-30

Start date

2024-11-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hospitalized patients who were treated adding imeglimin for more than 5 days on combination therapy with multiple daily insulin injection and DPP-4 inhibitors.

Exclusion criteria

Exclusion criteria: Type 1 diabetes Patients who couldn't continue to take imeglimin for more than 5 days Patients who have used drugs other than antidiabetic drugs that may cause fluctuations in blood glucose levels Patients who had been using antidiabetic drugs other than insulin or DPP-4 inhibitors before or within 5 days after starting Imeglimin. Patients who have had changes in their condition that may have led to fluctuations in blood glucose levels within 5 days after initiation of imeglimin. Patients considered ineligible for the study.

Design outcomes

Primary

Measure	Time frame
magnitude of changing insulin dosage from before to 5 days after initiation of imeglimin	—

Countries

Japan

Contacts

Public ContactFukumi Yoshikawa

Toho university school of medicine Division of Diabetes, Metabolism, and Endocrinology, Department of internal medicine.

fukumi.yoshikawa@med.toho-u.ac.jp0337624151

Outcome results